Servier Acquires BioNova's BN104 for Acute Leukemia Treatment
CompanyDeals

Servier Acquires BioNova’s BN104 for Acute Leukemia Treatment

ImmuneOnco and Instil Bio Announce Clinical Updates for IMM2510 in NSCLC
CompanyDrug

ImmuneOnco and Instil Bio Announce Clinical Updates for IMM2510 in NSCLC

UCB's Keppra Procurement Resumed in Shanghai After Regulatory Halt
CompanyDrug

UCB’s Keppra Procurement Resumed in Shanghai After Regulatory Halt

RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion
CompanyDeals

RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion

Ascletis Pharma Starts Phase I Study of ASC50 for Psoriasis in the US
CompanyDrug

Ascletis Pharma Starts Phase I Study of ASC50 for Psoriasis in the US

Jacobio Pharma's Glecirasib Approved by NMPA for KRAS G12C+ NSCLC
CompanyDrug

Jacobio Pharma’s Glecirasib Approved by NMPA for KRAS G12C+ NSCLC

AstraZeneca Shuts Down Neuroscience Research Group to Focus on Core Areas
Company

AstraZeneca Shuts Down Neuroscience Research Group to Focus on Core Areas

Hengrui Pharmaceuticals' Retagliptin and Metformin Approved by NMPA for Type 2 Diabetes
CompanyDrug

Hengrui Pharmaceuticals’ Retagliptin and Metformin Approved by NMPA for Type 2 Diabetes

Roche's Susvimo Gets FDA Approval for Diabetic Retinopathy
CompanyDrug

Roche’s Susvimo Gets FDA Approval for Diabetic Retinopathy

Joincare Pharmaceutical Plans to Acquire 64.81% Stake in Imexpharm for USD 220M
CompanyDeals

Joincare Pharmaceutical Plans to Acquire 64.81% Stake in Imexpharm for USD 220M

Chongqing Genrix Bio's GR2001 Tetanus Monoclonal Antibody NDA Accepted by NMPA
CompanyDrug

Chongqing Genrix Bio’s GR2001 Tetanus Monoclonal Antibody NDA Accepted by NMPA

Medtronic Plans to Spin Off Diabetes Business into Publicly Traded Entity
CompanyMedical Device

Medtronic Plans to Spin Off Diabetes Business into Publicly Traded Entity